In the last trading session, 1.02 million shares of the Cardiff Oncology Inc (NASDAQ:CRDF) were traded, and its beta was 1.72. Most recently the company’s share price was $4.58, and it changed around $0.08 or 1.78% from the last close, which brings the market valuation of the company to $304.65M. CRDF currently trades at a discount to its 52-week high of $6.42, offering almost -40.17% off that amount. The share price’s 52-week low was $1.63, which indicates that the current value has risen by an impressive 64.41% since then. We note from Cardiff Oncology Inc’s average daily trading volume that its 10-day average is 0.98 million shares, with the 3-month average coming to 2.12 million.
Cardiff Oncology Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 5 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended CRDF as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. Cardiff Oncology Inc is expected to report earnings per share of -0.25 for the current quarter.
Cardiff Oncology Inc (NASDAQ:CRDF) trade information
Instantly CRDF has showed a green trend with a performance of 1.78% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 4.83 on recent trading dayincreased the stock’s daily price by 5.18%. The company’s shares are currently up 5.53% year-to-date, but still up 14.21% over the last five days. On the other hand, Cardiff Oncology Inc (NASDAQ:CRDF) is 17.29% up in the 30-day period. We can see from the shorts that 9.48 million shares have been sold at a short interest cover period of 5.73 day(s).
Cardiff Oncology Inc (CRDF) estimates and forecasts
The year-over-year growth rate is expected to be 21.48%, up from the previous year.
Consensus estimates provided by 5 financial analysts predict the company will bring in an average of 73k in revenue for the current quarter. 5 analysts expect Cardiff Oncology Inc to make 76k in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 156k and 205k respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -53.21%. Forecasts for the next quarter put sales growth at -62.93%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 35.42%. Cardiff Oncology Inc earnings are expected to increase by -6.20% in 2025, but the outlook is negative -7.08% per year for the next five years.
CRDF Dividends
Cardiff Oncology Inc’s next quarterly earnings report is expected to be released in March.
Cardiff Oncology Inc (NASDAQ:CRDF)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 5.64% of Cardiff Oncology Inc shares, and 28.18% of them are in the hands of institutional investors. The stock currently has a share float of 29.86%. Cardiff Oncology Inc stock is held by 118.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 5.883% of the shares, which is about 2.63 million shares worth $5.84 million.
VANGUARD GROUP INC, with 4.7816% or 2.14 million shares worth $4.74 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
